CHATSWORTH, Calif.--(BUSINESS WIRE)--North American Scientific, Inc. (Nasdaq:NASI) announced today that it has decided to divest its NOMOS Radiation Oncology business. The Company will renew its focus on the marketing and development of innovative brachytherapy products for the treatment of cancer, including Prospera® brachytherapy seeds and SurTRAK™ needles and strands used primarily in the treatment of prostate cancer. The Company remains on track to commercialize its ClearPath™ multi-channel catheter breast brachytherapy devices in 2007. The ClearPath products are the only devices approved for both high-dose and continuous release, or low-dose, radiation treatments. The devices are designed to provide flexible, precise dose conformance and an innovative delivery system that is intended to offer a more advanced form of brachytherapy for the treatment of breast cancer.
